Strong mid-stage data on Pfizer's NSCLC drug

World drug giant Pfizer presented strong mid-stage data on its investigational compound, CP-751,871, in non-small cell lung cancer, at the 33rd Annual Congress of the European Society for Medical Oncology, held in Stockholm, Sweden.

Results from a Phase II, randomized, non-comparative study showed that 54% of patients with stage III/IV treatment-naive NSCLC receiving the combination CP-751,871 plus carboplatin and paclitaxel experienced objective responses. The response rate was 41% in patients treated with carboplatin and paclitaxel alone.

In addition, 78% of a subset of patients with squamous cell carcinoma and 57% of a cohort with adenocarcinoma receiving 20mg/kg of CP-751,871 plus carboplatin and paclitaxel experienced objective responses. Response rates were 46% and 25%, respectively, for squamous cell and adenocarcinoma patients receiving carboplatin and paclitaxel alone. No response advantage with CP-751,871 was seen in a subset of patients with undifferentiated tumors.